Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Holdings Lifted by BML Capital Management LLC

BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 62.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 2,186,191 shares of the biotechnology company's stock after purchasing an additional 837,153 shares during the period. Oramed Pharmaceuticals makes up approximately 3.1% of BML Capital Management LLC's portfolio, making the stock its 10th biggest holding. BML Capital Management LLC owned about 5.36% of Oramed Pharmaceuticals worth $5,334,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Murchinson Ltd. lifted its stake in shares of Oramed Pharmaceuticals by 23.2% in the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company's stock valued at $4,369,000 after purchasing an additional 320,495 shares during the period. Renaissance Technologies LLC increased its stake in Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company's stock worth $593,000 after buying an additional 108,700 shares during the period. Dimensional Fund Advisors LP lifted its position in Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock valued at $81,000 after purchasing an additional 10,774 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Oramed Pharmaceuticals in the first quarter worth approximately $68,000. Finally, XTX Topco Ltd bought a new stake in Oramed Pharmaceuticals in the second quarter worth approximately $40,000. Institutional investors own 12.73% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. StockNews.com cut shares of Oramed Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday. HC Wainwright reissued a "neutral" rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 0.9 %

NASDAQ:ORMP traded up $0.02 on Tuesday, hitting $2.34. 144,242 shares of the company's stock traded hands, compared to its average volume of 132,286. Oramed Pharmaceuticals Inc. has a 1 year low of $1.87 and a 1 year high of $3.67. The company has a market cap of $95.40 million, a PE ratio of 4.49 and a beta of 1.77. The firm has a 50-day moving average price of $2.38 and a 200-day moving average price of $2.38.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last released its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.01 by $0.21. On average, research analysts forecast that Oramed Pharmaceuticals Inc. will post 0.24 EPS for the current fiscal year.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.